REQUEST A DEMO
Total
USD $0.00
Search more companies

China Resources Boya Bio-Pharmaceutical Group Co., Ltd (China)

Main Activities: Electromedical and Electrotherapeutic Apparatus Manufacturing
Full name: China Resources Boya Bio-Pharmaceutical Group Co., Ltd Profile Updated: May 12, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

China Resources Boya Bio-Pharmaceutical Group Co., Ltd is a company located in Fuzhou, Jiangxi Province. It is the only designated blood product production unit in the province. The company specializes in the production of three main categories of products: albumin, immunoglobulin, and coagulation factors. It is one of the leading manufacturers of human blood albumin and intravenous human immunoglobulin in terms of product specifications. The company is also involved in the research and development of various other products, including coagulation factor VIII (AHG), prothrombin complex concentrate (PCC), human fibrin glue (FS), tetanus human immunoglobulin (HTIG), hand, foot, and mouth disease human immunoglobulin, and recombinant factor products. The company's products have been recognized by distributors and key cooperative hospitals for their excellent quality and have been awarded as new products or high-tech products in Jiangxi Province. On August 2, 2017, the company changed its name from "Jiangxi Boya Bio-Pharmaceutical Co., Ltd" to "Boya Bio-Pharmaceutical Group Co., Ltd." On March 22, 2022, the company changed its Chinese name from "Boya Bio-Pharmaceutical Group Co., Ltd" to "China Resources Boya Bio-Pharmaceutical Group Co., Ltd."

Headquarters
No. 333, Huiquan Road, High-tech Industrial Park, Fuzhou City, Jiangxi Province
Fuzhou; Jiangxi; Postal Code: 344000

Contact Details: Purchase the China Resources Boya Bio-Pharmaceutical Group Co., Ltd report to view the information.

Website: http://www.china-boya.com

Basic Information
Total Employees:
Purchase the China Resources Boya Bio-Pharmaceutical Group Co., Ltd report to view the information.
Outstanding Shares:
Purchase the China Resources Boya Bio-Pharmaceutical Group Co., Ltd report to view the information.
Registered Capital:
Purchase the China Resources Boya Bio-Pharmaceutical Group Co., Ltd report to view the information.
Financial Auditors:
Purchase the China Resources Boya Bio-Pharmaceutical Group Co., Ltd report to view the information.
Incorporation Date:
November 06, 1993
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
29.28%
Purchase this report to view the information.
11.31%
Purchase this report to view the information.
4.51%
Purchase this report to view the information.
3.78%
Purchase this report to view the information.
2.98%
Subsidiaries
Beijing Boya Xinnuo Biological Technology Co., Ltd.
100%
Chongren County Boya Single Collection Plasma Co., Ltd.
100%
Duchang County Boya Single Collection Plasma Co., Ltd.
100%
Company Performance
Financial values in the chart are available after China Resources Boya Bio-Pharmaceutical Group Co., Ltd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
-44.36%
Total operating revenue
-44.39%
Operating profit (EBIT)
-14.93%
EBITDA
-13.96%
Net Profit (Loss) for the Period
-12.97%
Total assets
-2.48%
Total equity
0.64%
Operating Profit Margin (ROS)
13.48%
Net Profit Margin
12.2%
Return on Equity (ROE)
-0.32%
Quick Ratio
5.17%
Cash Ratio
1.62%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?